🇺🇸 FDA
Patent

US 9173896

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

granted A61KA61K31/713A61P

Quick answer

US patent 9173896 (RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions) held by Arrowhead Research Corporation expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Research Corporation
Grant date
Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/713, A61P, A61P27/02, A61P27/06